Does the media prefer RCUS or ELAN?

In the previous week, Elanco Animal Health had 3 more articles in the media than Arcus Biosciences. MarketBeat recorded 9 mentions for Elanco Animal Health and 6 mentions for Arcus Biosciences. Elanco Animal Health's average media sentiment score of 0.72 beat Arcus Biosciences' score of 0.27 indicating that Elanco Animal Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcus Biosciences 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Elanco Animal Health 6 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer RCUS or AXSM?

In the previous week, Axsome Therapeutics had 5 more articles in the media than Arcus Biosciences. MarketBeat recorded 11 mentions for Axsome Therapeutics and 6 mentions for Arcus Biosciences. Axsome Therapeutics' average media sentiment score of 0.77 beat Arcus Biosciences' score of 0.27 indicating that Axsome Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcus Biosciences 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Axsome Therapeutics 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ARWR or RCUS?

In the previous week, Arrowhead Pharmaceuticals had 15 more articles in the media than Arcus Biosciences. MarketBeat recorded 21 mentions for Arrowhead Pharmaceuticals and 6 mentions for Arcus Biosciences. Arrowhead Pharmaceuticals' average media sentiment score of 1.07 beat Arcus Biosciences' score of 0.27 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arrowhead Pharmaceuticals 9 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arcus Biosciences 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is ABVX or RCUS more profitable?

Abivax has a net margin of 0.00% compared to Arcus Biosciences' net margin of -156.36%. Arcus Biosciences' return on equity of -68.97% beat Abivax's return on equity. Company Net Margins Return on Equity Return on Assets Abivax N/A -99.02% -70.26% Arcus Biosciences -156.36% -68.97% -35.27%

Does the media refer more to ABVX or RCUS?

In the previous week, Abivax had 7 more articles in the media than Arcus Biosciences. MarketBeat recorded 13 mentions for Abivax and 6 mentions for Arcus Biosciences. Abivax's average media sentiment score of 1.41 beat Arcus Biosciences' score of 0.27 indicating that Abivax is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abivax 12 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arcus Biosciences 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to RCUS or SMMT?

In the previous week, Summit Therapeutics had 7 more articles in the media than Arcus Biosciences. MarketBeat recorded 13 mentions for Summit Therapeutics and 6 mentions for Arcus Biosciences. Summit Therapeutics' average media sentiment score of 0.35 beat Arcus Biosciences' score of 0.27 indicating that Summit Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcus Biosciences 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Summit Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Arcus Biosciences (RCUS) Competitors

$27.78 -0.41 (-1.46%)

As of 11:40 AM Eastern

Compare

RCUS vs. ELAN, AXSM, ARWR, ABVX, and SMMT

Should you buy Arcus Biosciences stock or one of its competitors? MarketBeat compares Arcus Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Arcus Biosciences include Elanco Animal Health (ELAN), Axsome Therapeutics (AXSM), Arrowhead Pharmaceuticals (ARWR), Abivax (ABVX), and Summit Therapeutics (SMMT).

How does Arcus Biosciences compare to Elanco Animal Health?

Arcus Biosciences (NYSE:RCUS) and Elanco Animal Health (NYSE:ELAN) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, risk, dividends, institutional ownership, media sentiment, profitability and analyst recommendations.

Elanco Animal Health has higher revenue and earnings than Arcus Biosciences. Elanco Animal Health is trading at a lower price-to-earnings ratio than Arcus Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcus Biosciences	$236M	14.80	-$353M	-$3.18	N/A
Elanco Animal Health	$4.89B	2.62	-$232M	-$0.50	N/A

Arcus Biosciences presently has a consensus target price of $36.40, suggesting a potential upside of 31.03%. Elanco Animal Health has a consensus target price of $28.73, suggesting a potential upside of 12.04%. Given Arcus Biosciences' higher possible upside, equities research analysts clearly believe Arcus Biosciences is more favorable than Elanco Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcus Biosciences	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77

Elanco Animal Health has a net margin of -4.95% compared to Arcus Biosciences' net margin of -156.36%. Elanco Animal Health's return on equity of 7.42% beat Arcus Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcus Biosciences	-156.36%	-68.97%	-35.27%
Elanco Animal Health	-4.95%	7.42%	3.66%

In the previous week, Elanco Animal Health had 3 more articles in the media than Arcus Biosciences. MarketBeat recorded 9 mentions for Elanco Animal Health and 6 mentions for Arcus Biosciences. Elanco Animal Health's average media sentiment score of 0.72 beat Arcus Biosciences' score of 0.27 indicating that Elanco Animal Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcus Biosciences	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Elanco Animal Health	6 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Arcus Biosciences has a beta of 0.8, indicating that its stock price is 20% less volatile than the broader market. Comparatively, Elanco Animal Health has a beta of 1.68, indicating that its stock price is 68% more volatile than the broader market.

92.9% of Arcus Biosciences shares are held by institutional investors. Comparatively, 97.5% of Elanco Animal Health shares are held by institutional investors. 7.6% of Arcus Biosciences shares are held by insiders. Comparatively, 1.1% of Elanco Animal Health shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Elanco Animal Health beats Arcus Biosciences on 13 of the 17 factors compared between the two stocks.

How does Arcus Biosciences compare to Axsome Therapeutics?

Arcus Biosciences (NYSE:RCUS) and Axsome Therapeutics (NASDAQ:AXSM) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations, media sentiment and risk.

Axsome Therapeutics has a net margin of -26.59% compared to Arcus Biosciences' net margin of -156.36%. Arcus Biosciences' return on equity of -68.97% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcus Biosciences	-156.36%	-68.97%	-35.27%
Axsome Therapeutics	-26.59%	-267.16%	-28.53%

Arcus Biosciences has a beta of 0.8, suggesting that its share price is 20% less volatile than the broader market. Comparatively, Axsome Therapeutics has a beta of 0.65, suggesting that its share price is 35% less volatile than the broader market.

Arcus Biosciences currently has a consensus target price of $36.40, indicating a potential upside of 31.03%. Axsome Therapeutics has a consensus target price of $261.29, indicating a potential upside of 24.90%. Given Arcus Biosciences' higher probable upside, equities research analysts clearly believe Arcus Biosciences is more favorable than Axsome Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcus Biosciences	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58
Axsome Therapeutics	2 Sell rating(s)	0 Hold rating(s)	19 Buy rating(s)	2 Strong Buy rating(s)	2.91

92.9% of Arcus Biosciences shares are owned by institutional investors. Comparatively, 81.5% of Axsome Therapeutics shares are owned by institutional investors. 7.6% of Arcus Biosciences shares are owned by insiders. Comparatively, 20.6% of Axsome Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Axsome Therapeutics has higher revenue and earnings than Arcus Biosciences. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Arcus Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcus Biosciences	$236M	14.80	-$353M	-$3.18	N/A
Axsome Therapeutics	$638.50M	16.86	-$183.17M	-$3.73	N/A

In the previous week, Axsome Therapeutics had 5 more articles in the media than Arcus Biosciences. MarketBeat recorded 11 mentions for Axsome Therapeutics and 6 mentions for Arcus Biosciences. Axsome Therapeutics' average media sentiment score of 0.77 beat Arcus Biosciences' score of 0.27 indicating that Axsome Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcus Biosciences	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Axsome Therapeutics	6 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Axsome Therapeutics beats Arcus Biosciences on 11 of the 17 factors compared between the two stocks.

How does Arcus Biosciences compare to Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals (NASDAQ:ARWR) and Arcus Biosciences (NYSE:RCUS) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, media sentiment, dividends, earnings and analyst recommendations.

Arrowhead Pharmaceuticals has higher revenue and earnings than Arcus Biosciences. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Arcus Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arrowhead Pharmaceuticals	$829.45M	14.32	-$1.63M	-$2.15	N/A
Arcus Biosciences	$236M	14.80	-$353M	-$3.18	N/A

In the previous week, Arrowhead Pharmaceuticals had 15 more articles in the media than Arcus Biosciences. MarketBeat recorded 21 mentions for Arrowhead Pharmaceuticals and 6 mentions for Arcus Biosciences. Arrowhead Pharmaceuticals' average media sentiment score of 1.07 beat Arcus Biosciences' score of 0.27 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arrowhead Pharmaceuticals	9 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Arcus Biosciences	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

62.6% of Arrowhead Pharmaceuticals shares are owned by institutional investors. Comparatively, 92.9% of Arcus Biosciences shares are owned by institutional investors. 3.6% of Arrowhead Pharmaceuticals shares are owned by insiders. Comparatively, 7.6% of Arcus Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Arrowhead Pharmaceuticals has a beta of 1.27, meaning that its share price is 27% more volatile than the broader market. Comparatively, Arcus Biosciences has a beta of 0.8, meaning that its share price is 20% less volatile than the broader market.

Arrowhead Pharmaceuticals presently has a consensus price target of $96.92, suggesting a potential upside of 14.93%. Arcus Biosciences has a consensus price target of $36.40, suggesting a potential upside of 31.03%. Given Arcus Biosciences' higher possible upside, analysts plainly believe Arcus Biosciences is more favorable than Arrowhead Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arrowhead Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62
Arcus Biosciences	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58

Arrowhead Pharmaceuticals has a net margin of -48.38% compared to Arcus Biosciences' net margin of -156.36%. Arrowhead Pharmaceuticals' return on equity of -55.09% beat Arcus Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arrowhead Pharmaceuticals	-48.38%	-55.09%	-18.13%
Arcus Biosciences	-156.36%	-68.97%	-35.27%

Summary

Arrowhead Pharmaceuticals beats Arcus Biosciences on 11 of the 16 factors compared between the two stocks.

How does Arcus Biosciences compare to Abivax?

Abivax (NASDAQ:ABVX) and Arcus Biosciences (NYSE:RCUS) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, earnings, media sentiment and analyst recommendations.

Abivax currently has a consensus price target of $156.50, suggesting a potential upside of 26.47%. Arcus Biosciences has a consensus price target of $36.40, suggesting a potential upside of 31.03%. Given Arcus Biosciences' higher probable upside, analysts clearly believe Arcus Biosciences is more favorable than Abivax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abivax	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80
Arcus Biosciences	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58

Abivax has a net margin of 0.00% compared to Arcus Biosciences' net margin of -156.36%. Arcus Biosciences' return on equity of -68.97% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abivax	N/A	-99.02%	-70.26%
Arcus Biosciences	-156.36%	-68.97%	-35.27%

Abivax has a beta of 0.87, indicating that its stock price is 13% less volatile than the broader market. Comparatively, Arcus Biosciences has a beta of 0.8, indicating that its stock price is 20% less volatile than the broader market.

Arcus Biosciences has higher revenue and earnings than Abivax. Abivax is trading at a lower price-to-earnings ratio than Arcus Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abivax	N/A	N/A	-$380.27M	-$5.21	N/A
Arcus Biosciences	$236M	14.80	-$353M	-$3.18	N/A

In the previous week, Abivax had 7 more articles in the media than Arcus Biosciences. MarketBeat recorded 13 mentions for Abivax and 6 mentions for Arcus Biosciences. Abivax's average media sentiment score of 1.41 beat Arcus Biosciences' score of 0.27 indicating that Abivax is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abivax	12 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Arcus Biosciences	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

47.9% of Abivax shares are owned by institutional investors. Comparatively, 92.9% of Arcus Biosciences shares are owned by institutional investors. 7.6% of Arcus Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Arcus Biosciences beats Abivax on 9 of the 15 factors compared between the two stocks.

How does Arcus Biosciences compare to Summit Therapeutics?

Arcus Biosciences (NYSE:RCUS) and Summit Therapeutics (NASDAQ:SMMT) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, valuation, risk, media sentiment and analyst recommendations.

92.9% of Arcus Biosciences shares are owned by institutional investors. Comparatively, 4.6% of Summit Therapeutics shares are owned by institutional investors. 7.6% of Arcus Biosciences shares are owned by company insiders. Comparatively, 83.5% of Summit Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summit Therapeutics has a net margin of 0.00% compared to Arcus Biosciences' net margin of -156.36%. Arcus Biosciences' return on equity of -68.97% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcus Biosciences	-156.36%	-68.97%	-35.27%
Summit Therapeutics	N/A	-168.94%	-141.92%

Arcus Biosciences has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Arcus Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcus Biosciences	$236M	14.80	-$353M	-$3.18	N/A
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.12	N/A

Arcus Biosciences has a beta of 0.8, indicating that its share price is 20% less volatile than the broader market. Comparatively, Summit Therapeutics has a beta of -1.23, indicating that its share price is 223% less volatile than the broader market.

In the previous week, Summit Therapeutics had 7 more articles in the media than Arcus Biosciences. MarketBeat recorded 13 mentions for Summit Therapeutics and 6 mentions for Arcus Biosciences. Summit Therapeutics' average media sentiment score of 0.35 beat Arcus Biosciences' score of 0.27 indicating that Summit Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcus Biosciences	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Summit Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Arcus Biosciences presently has a consensus price target of $36.40, suggesting a potential upside of 31.03%. Summit Therapeutics has a consensus price target of $26.15, suggesting a potential upside of 100.34%. Given Summit Therapeutics' higher possible upside, analysts plainly believe Summit Therapeutics is more favorable than Arcus Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcus Biosciences	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58
Summit Therapeutics	2 Sell rating(s)	6 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.44

Summary

Arcus Biosciences beats Summit Therapeutics on 9 of the 16 factors compared between the two stocks.

Get Arcus Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RCUS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RCUS vs. The Competition

Export

Metric	Arcus Biosciences	Biotechnology Industry	Healthcare Sector	NYSE Exchange
Market Cap	$3.48B	$3.52B	$6.79B	$23.74B
Dividend Yield	N/A	3.78%	2.59%	4.21%
P/E Ratio	-8.71	7.39	282.14	31.44
Price / Sales	14.80	1,212.47	573.43	164.82
Price / Cash	N/A	44.80	28.60	18.73
Price / Book	4.76	17.11	11.09	4.81
Net Income	-$353M	-$12.56M	$3.49B	$1.07B
7 Day Performance	-0.74%	-0.59%	0.42%	0.68%
1 Month Performance	-8.68%	-7.44%	-4.33%	0.44%
1 Year Performance	203.26%	49.84%	63.09%	20.45%

Arcus Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RCUS Arcus Biosciences	2.8133 of 5 stars	$27.78 -1.5%	$36.40 +31.0%	+207.6%	$3.48B	$236M	N/A	500	Upcoming Earnings
ELAN Elanco Animal Health	3.0868 of 5 stars	$25.48 +2.3%	$28.73 +12.7%	+91.5%	$12.44B	$4.89B	N/A	9,400	Positive News Upcoming Earnings Analyst Upgrade
AXSM Axsome Therapeutics	3.5889 of 5 stars	$238.37 -1.1%	$261.48 +9.7%	+111.6%	$12.40B	$638.50M	N/A	380	Upcoming Earnings Analyst Forecast
ARWR Arrowhead Pharmaceuticals	2.3344 of 5 stars	$85.53 -0.1%	$95.08 +11.2%	+431.4%	$12.06B	$829.45M	N/A	400	Positive News Upcoming Earnings
ABVX Abivax	3.9321 of 5 stars	$128.00 +1.8%	$156.50 +22.3%	+73.6%	$10.96B	N/A	N/A	61	Positive News Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:RCUS) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Arcus Biosciences (RCUS) Competitors

RCUS vs. ELAN, AXSM, ARWR, ABVX, and SMMT

How does Arcus Biosciences compare to Elanco Animal Health?

Summary

How does Arcus Biosciences compare to Axsome Therapeutics?

Summary

How does Arcus Biosciences compare to Arrowhead Pharmaceuticals?

Summary

How does Arcus Biosciences compare to Abivax?

Summary

How does Arcus Biosciences compare to Summit Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RCUS vs. The Competition

Arcus Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Arcus Biosciences (RCUS) Competitors

RCUS vs. ELAN, AXSM, ARWR, ABVX, and SMMT

How does Arcus Biosciences compare to Elanco Animal Health?

Which has better earnings & valuation, RCUS or ELAN?

Do analysts rate RCUS or ELAN?

Is RCUS or ELAN more profitable?

Does the media prefer RCUS or ELAN?

Which has more risk and volatility, RCUS or ELAN?

Do institutionals & insiders hold more shares of RCUS or ELAN?

Summary

How does Arcus Biosciences compare to Axsome Therapeutics?

Is RCUS or AXSM more profitable?

Which has more risk and volatility, RCUS or AXSM?

Do analysts recommend RCUS or AXSM?

Do institutionals and insiders have more ownership in RCUS or AXSM?

Which has better valuation and earnings, RCUS or AXSM?

Does the media prefer RCUS or AXSM?

Summary

How does Arcus Biosciences compare to Arrowhead Pharmaceuticals?

Which has better earnings and valuation, ARWR or RCUS?

Does the media refer more to ARWR or RCUS?

Do insiders & institutionals hold more shares of ARWR or RCUS?

Which has more risk & volatility, ARWR or RCUS?

Do analysts prefer ARWR or RCUS?

Is ARWR or RCUS more profitable?

Summary

How does Arcus Biosciences compare to Abivax?

Do analysts prefer ABVX or RCUS?

Is ABVX or RCUS more profitable?

Which has more risk and volatility, ABVX or RCUS?

Which has higher valuation and earnings, ABVX or RCUS?

Does the media refer more to ABVX or RCUS?

Do institutionals and insiders hold more shares of ABVX or RCUS?

Summary

How does Arcus Biosciences compare to Summit Therapeutics?

Do insiders & institutionals hold more shares of RCUS or SMMT?

Is RCUS or SMMT more profitable?

Which has better valuation & earnings, RCUS or SMMT?

Which has more risk & volatility, RCUS or SMMT?

Does the media refer more to RCUS or SMMT?

Do analysts prefer RCUS or SMMT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RCUS vs. The Competition

Arcus Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools